Page 1

hikma . Hikma delivers another strong financial and operational performance and improves FY outlook for Generics London , 6 August 2021 Hikma Pharmaceuticals PLC ( ' Hikma ' or ' Group ' ) , the multinational pharmaceutical company , today reports its interim results for the six months ended 30 June 2021 . Siggi Olafsson , Chief Executive Officer of Hikma , said : " Once again , we have benefited from the resilience of our portfolio and our flexible manufacturing footprint . Our strong performance included solid year - over - year increases in revenue and operating profit , underscoring our ability to generate positive results in challenging market conditions . We are continuing to benefit from investments we have made to build our pipeline of new medicines and our progress in the first half underpins our improved outlook for the full year . Looking ahead , our clear strategy , strong pipeline and agility give us the confidence to drive continued growth and deliver increased value to all our stakeholders . " Highlights : Reported results ( statutory ) $ million Revenue Operating profit Profit attributable to shareholders Cashflow from operating activities Basic earnings per share ( cents ) ² Interim dividend per share ( cents ) ² Core results ³ ( underlying ) $ million Core revenue Core operating profit Core profit attributable to shareholders Core basic earnings per share ( cents ) ² H1 2021 1,216 Press Release 326 248 224 107.4 18.0 H1 2021 1,216 309 223 96.5 H1 2020 1,132 297 212 292 87.6 16.0 H1 2020 1,132 284 205 85.3 Change 7 % 10 % 17 % ( 23 ) % 23 % 13 % Change 7 % 9 % 9 % 13 % Constant currency¹ change 7 % 15 % 26 % 1 Constant currency numbers in H1 2021 represent reported H1 2021 numbers translated using H1 2020 exchange rates , excluding price increases in the business resulting from the devaluation of currencies and excluding the impact from hyperinflation accounting . Lebanon and Sudan are considered hyperinflationary economies , therefore the spot exchange rate as at 30 June 2021 was used to translate the results of these operations into US dollars 32 % Constant currency¹ change 7 % 15 % 18 % 23 % 2 In June 2020 , Hikma purchased 12.8 million ordinary shares from Boehringer Ingelheim , which are being held in treasury . Core results throughout the document are presented to show the underlying performance of the Group , excluding the exceptional items and other adjustments set out in Note 5. Core results are a non - IFRS measure and a reconciliation to reported IFRS measures is provided on page 14